AOD-9604 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Small early-phase human trials from the 2000s; program did not proceed through full clinical development for an approved indication.

Animal evidence: Rodent lipolysis studies form the primary evidence base.

Introduction & Mechanism of Action

Modified fragment of human growth hormone (176-191) studied for fat-metabolism research without GH growth effects.

Isolates the lipolytic (fat-metabolizing) region of the GH molecule while omitting the region responsible for growth-promoting and insulin-resistance effects, in principle.

Receptors/targets: Beta-3 adrenergic receptor (proposed mechanism in preclinical models)

Areas of Research Interest

• Lipolysis research
• Fat-metabolism studies

Benefits Reported in Research

• Lipolysis research
• Fat-metabolism studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 300–500 mcg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on AOD-9604 reports administration at 300–500 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site irritation
• Headache (reported anecdotally, not well quantified in trials)

Contraindications

• Pregnancy
• Known hypersensitivity to GH-derived peptides

Drug interactions

• Not well characterized due to limited human trial data

Safety

• Injection-site reactions
• Largely unknown long-term risk given sparse human data

Derived from a growth-hormone fragment but studied specifically for metabolic (not growth) effects; long-term human safety data is limited.

Expected Results & Comparison

AOD-9604 and 5-Amino-1MQ are both studied for fat-metabolism effects via different mechanisms (a GH-fragment vs. an NNMT-inhibiting small molecule) — neither has strong modern human trial support, so comparing potency between them is not evidence-based.

References

Continue